10x Genomics, Inc. Class A Common Stock

TXG trades at an 18.82% short interest—substantially elevated for a biotech instrumentation play—yet RSI sits at a neutral 43.0, suggesting the stock hasn't been hammered into oversold territory despite bearish positioning. The $2.8B market cap and unprofitable status (n/a P/E) point to a growth-stage story still proving its economics. The absence of overbought conditions combined with meaningful short exposure creates potential squeeze dynamics, though the lack of extreme technical extremes means any move would require genuine catalyst support rather than pure technicals. The setup implies cautious skepticism from the market, but without clear deterioration priced in yet.